Available Until 4/22/2023

COVID-19 Monoclonal Antibody Toolkit

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 View more SIDPEC Activities 


Monoclonal antibody (mAb) therapy has exhibited clinical benefit for treatment of mild-to-moderate COVID-19 in non-hospitalized patients who are at high risk for progression to severe disease. More recently, certain mAbs have been approved for post-exposure prophylaxis (PEP) of COVID-19 in high-risk individuals. Pharmacists in various practice settings have opportunities to impact patient care related to use of mAb in COVID-19. This CE program is intended to educate pharmacists on available mAb therapeutics, highlight their role in treatment and PEP of COVID-19, and provide resources for infusion sites offering mAb to patients. Click here for the latest COVID-19 Monoclonal Antibody Toolkit.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this CE activity the participant will be able to do the following in regard to specific treatments being considered for COVID-19:

  • Recognize key stakeholders and aspects of a monoclonal antibody (mAb) infusion site.
  • Outline clinical characteristics that would make patients appropriate candidates for mAb therapy.
  • Identify resources necessary for mAb preparation and administration.
  • Review clinical data, national guidelines, and drug-specific guidance for available mAb therapeutics.


Kristen Zeitler, BS, PharmD, BCPS
Pharmacotherapy Specialist, Infectious Diseases
Tampa General Hospital
Tampa, FL


Release Date: April 22, 2022
Expiration Date: April 22, 2023


ACPE LogoThis activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-22-158-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 2.0 contact hours (0.2 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.


ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Dr. Zeitler has no relevant commercial or financial relationships to disclose.


This activity is supported by educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.